Posted innews
新诊断的儿童免疫性血小板减少症中使用艾曲波帕：早期治疗策略的突破
这项随机试验表明，艾曲波帕显著改善了新诊断为ITP的儿童的持续血小板反应，提供了一种潜在的早期干预选择。
Posted inNeurology Specialties
Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial
This phase III trial evaluated oral valiltramiprosate in APOEε4/ε4 homozygotes with early Alzheimer's, showing brain atrophy slowing but limited overall clinical benefit, with nominal improvements in mild cognitive impairment subgroups.
Posted inDiabetes & Endocrinology Specialties
Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial
The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.
Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review
This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.
Posted inNephrology news Oncology
Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib
This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.
IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial
The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.
Posted inAnesthesiology Critical Care news
Individualized Perioperative Blood Pressure Management in Major Abdominal Surgery: Insights from the IMPROVE-multi Trial
The IMPROVE-multi randomized clinical trial found that tailoring perioperative blood pressure targets to individual preoperative nighttime MAP levels did not reduce postoperative organ injury or mortality compared to routine management in high-risk major abdominal surgery patients.
Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial
In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.
Posted inGastroenterology Internal Medicine
Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial
The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.
Posted inClinical Updates news Oncology Specialties
Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial
A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.
Posted inDiabetes & Endocrinology news Specialties
Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management
Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies.
Posted inClinical Updates Neurology news
Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease
This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson's disease patients previously stable on continuous DBS.
Posted innews Psychiatry
Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials
Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.
Posted inRespiratory Specialties
MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management
The MACRO trial demonstrates that endoscopic sinus surgery significantly improves quality of life in adults with chronic rhinosinusitis, while long-term low-dose clarithromycin shows no added benefit over placebo.
Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, highlighting the need for longer, strengthened treatments.
Posted inNeurology news Specialties
Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial
A multi-center, triple-blind phase 2 trial demonstrates that daily candesartan 16 mg significantly reduces migraine days in episodic migraine patients, with tolerable safety profiles, supporting its role as an effective preventive option.
Posted innews Oncology Specialties
Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results
The NRG Oncology BN007 trial found that combining ipilimumab with nivolumab did not improve progression-free survival compared to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma, leading to early closure of the study before phase III.
Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and diabetic populations.
Posted inClinical Updates Oncology
Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.
Reevaluating Early Blood Pressure Targets in Acute Spinal Cord Injury: Insights from a Multicenter Randomized Trial
A recent randomized clinical trial comparing augmented to conventional blood pressure targets in acute spinal cord injury found no improvement in 6-month neurological outcomes, challenging current practices and highlighting risks of higher blood pressure management.